Alector (ALEC) is a clinical-stage biotech company looking to treat neurological disorders like frontotemporal dementia and Alzheimer's disease and also potentially cancer as well. Alector's lead program is AL001 for treatment of frontotemporal dementia patients with a single GRN mutation, and it has been given an orphan drug designation from the FDA due to the complete lack of current treatment options for these patients. Alector recently was trading in the $20s and $30s but has dropped dramatically into the mid-teens after releasing top-line, preliminary data from its ongoing AL001 Phase 2 trial. In this article,